BTN2A1

Across TCGA pan-cancer cohorts, BTN2A1 mass-spec protein is linked to patient survival in 8 of 34 cancer types, making it a survival-associated BTN2A1 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher BTN2A1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BTN2A1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and OV show a favorable association.

PDAC, CCRCC, and OV are the cancer types where BTN2A1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	II,III,IV	0.251	0.699	.005	20	view →
CCRCC	OS	Median	All	1.000	0.909	.019	7	view →
OV	DFS	Tertile	All	1.000	0.678	.026	4	view →
GBM	OS	Tertile	All	0.297	0.483	.031	2	view →
HNSC	DFS	Tertile	All	1.000	0.904	.036	2	view →
LSCC	OS	Median	III,IV	0.790	0.432	.033	2	view →
UCEC	OS	Quartile	All	1.000	0.852	.023	2	view →
LUAD	DFS	Tertile	All	0.931	0.462	.017	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

BTN2A1–PDAC (OS)

Open the PDAC breakdown →